For research use only. Not for therapeutic Use.
RO27-3225 TFA is potent and selective melanocortin 4 receptor (MC4R) agonist with an EC50 of 1 nM and 8 nM for MC4R and MC1R, respectively. RO27-3225 TFA shows ~30-fold selectivity for MC4R over MC3R. RO27-3225 TFA has neuroprotective and anti-inflammatory effects[1][2][3].
RO27-3225 (0.012-0.048 mg/kg; intravenous injection; Wistar rats) treatment reverses haemorrhagic shock, reduces multiple organ damage and improves survival. RO27-3225 could have a protective role against multiple organ failure following circulatory shock[2].
| Catalog Number | I045905 |
| Molecular Formula | C41H53F3N12O8 |
| Purity | ≥95% |
| Reference | [1]. Benoit SC, et al. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J Neurosci. 2000 May 1;20(9):3442-8. [2]. Giuliani D, et al. Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage. Br J Pharmacol. 2007 Mar;150(5):595-603. [3]. Zhang Y, et al. Effects of RO27-3225 on neurogenesis, PDGFRβ+ cells and neuroinflammation after cerebral infarction. Int Immunopharmacol. 2020 Feb 11;81:106281. |
